86 related articles for article (PubMed ID: 37793348)
1. Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists.
Xu X; Feng J; Cui Y; Li P; Dong J; Liao L
J Diabetes; 2024 Jun; 16(6):e13566. PubMed ID: 38753662
[TBL] [Abstract][Full Text] [Related]
2. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.
Currie G; Taylor AH; Fujita T; Ohtsu H; Lindhardt M; Rossing P; Boesby L; Edwards NC; Ferro CJ; Townend JN; van den Meiracker AH; Saklayen MG; Oveisi S; Jardine AG; Delles C; Preiss DJ; Mark PB
BMC Nephrol; 2016 Sep; 17(1):127. PubMed ID: 27609359
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
Kintscher U
Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease.
Baran W; Krzemińska J; Szlagor M; Wronka M; Młynarska E; Franczyk B; Rysz J
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576158
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.
Oraii A; Healey JS; Kowalik K; Pandey AK; Benz AP; Wong JA; Conen D; McIntyre WF
Eur Heart J; 2024 Mar; 45(10):756-774. PubMed ID: 38195054
[TBL] [Abstract][Full Text] [Related]
6. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
Kolkhof P; Bärfacker L
J Endocrinol; 2017 Jul; 234(1):T125-T140. PubMed ID: 28634268
[TBL] [Abstract][Full Text] [Related]
7. Incidence and progression of atrial fibrillation in patients with and without heart failure using mineralocorticoid receptor antagonists: a meta-analysis.
Sampaio Rodrigues T; Garcia Quarto LJ; Nogueira SC; Koshy AN; Mahajan R; Sanders P; Ekinci EI; Burrell LM; Farouque O; Lim HS
Clin Res Cardiol; 2024 Jun; 113(6):884-897. PubMed ID: 38170251
[TBL] [Abstract][Full Text] [Related]
8. Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys.
Cohen JB; Bancos I; Brown JM; Sarathy H; Turcu AF; Cohen DL
Annu Rev Med; 2023 Jan; 74():217-230. PubMed ID: 36375469
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptor antagonists and reno-protection: What's the evidence & where do they fit? A guide for non-specialists.
Bakris G
Diabetes Obes Metab; 2024 May; ():. PubMed ID: 38715476
[TBL] [Abstract][Full Text] [Related]
10. Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials.
Saito R; Nakada T
Drug Metab Pharmacokinet; 2024 Jun; 56():101019. PubMed ID: 38797092
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor antagonists in kidney transplantation.
Kanbay M; Copur S; Mizrak B; Mallamaci F; Zoccali C
Eur J Clin Invest; 2024 Apr; ():e14206. PubMed ID: 38578116
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy Use and Associated Events in Clinical Practice Following Dissemination of Trial Findings: A De-Implementation Study Using Interrupted Time Series Analysis.
Campbell HM; Murata AE; Henrie AM; Conner TA
Clin Ther; 2024 Jan; 46(1):40-49. PubMed ID: 37953077
[TBL] [Abstract][Full Text] [Related]
13. Improvement in proteinuria with sodium-glucose cotransporter 2 inhibitors and esaxerenone treatment in patients with chronic allograft kidney disease: A case report.
Daimon S
Clin Nephrol Case Stud; 2024; 12():26-31. PubMed ID: 38516340
[TBL] [Abstract][Full Text] [Related]
14. Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis.
Yuan CY; Gao YC; Lin Y; Liu L; Shen XG; Zou WL; Wang MM; Shen QQ; Shao LN; Liu YM; Zhang JW; Pan ZH; Zhu Y; Yu JT; Yu XG; Zhu B
Am J Nephrol; 2024; 55(1):1-17. PubMed ID: 37793348
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
Chen Q; Wei G; Wang Y; Li X; Zhao Q; Zhu L; Xiao Q; Xiong X
Front Pharmacol; 2024; 15():1338044. PubMed ID: 38476327
[No Abstract] [Full Text] [Related]
18. Mineralocorticoid antagonists in chronic kidney disease.
Dhaybi OA; Bakris G
Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):50-55. PubMed ID: 27753685
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
